A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumors
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select advanced solid tumors.
• Histologic confirmation of advanced solid tumors
• Subjects must have recurrent/metastatic disease and may have been previously treated in the recurrent/metastatic setting.
Multiple Tumor Types
Rom Leidner, M.D.
- Oncology and Hematology Care Eastside